Lercanidipino Tecnigen (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that is required for muscle contraction. This inhibition causes the arteries to dilate, decreasing peripheral resistance and consequently lowering systemic arterial pressure.

The appropriate dose of lercanidipine is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with a lower incidence of certain side effects such as peripheral edema, though individual response varies.

Lercanidipino Tecnigen should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

Serious adverse events, though rare, include severe hypotension, angioedema, and myocardial infarction. Patients should seek immediate medical attention if they experience sudden swelling of the face or throat, a rapid drop in blood pressure, or chest pain.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis or uncontrolled heart failure unless specifically advised by a cardiologist.